PSMA-targeted low-molecular double conjugates for diagnostics and therapy

This review presents data on dual conjugates of therapeutic and diagnostic action for targeted delivery to prostate cancer cells. The works of the last ten years on this topic were analyzed. The mail attention focuses on low-molecular-weight conjugates directed to the prostate-specific membrane antigen (PSMA); the comparison of high and low molecular weight PSMA-targeted conjugates was made. The considered conjugates were divided in the review into two main classes: diagnostic bimodal conjugates (which are containing two fragments for different types of diagnostics), theranostic conjugates (containing both therapeutic and diagnostic agents); also bimodal high molecular weight therapeutic conjugates containing two therapeutic agents are briefly discussed. The data of in vitro and in vivo studies for PSMA-targeted double conjugates available by the beginning of 2021 have been analyzed. (C) 2021 Elsevier Masson SAS. All rights reserved.

Automated summary

This review discusses the use of dual conjugates for targeted delivery to prostate cancer cells, focusing on low-molecular-weight conjugates directed to PSMA, and comparing high and low molecular weight PSMA-targeted conjugates. It also categorizes the conjugates into diagnostic bimodal and theranostic conjugates, as well as briefly mentioning bimodal high molecular weight therapeutic conjugates with two therapeutic agents. In vitro and in vivo studies for PSMA-targeted double conjugates available by the beginning of 2021 were analyzed.